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ABSTRACT
Capicua (CIC) has been implicated in pathogenesis of spinocerebellar ataxia 
type-1 (SCA1) neurodegenerative disease and some types of cancer; however, the 
role of CIC in prostate cancer remains unknown. Here we show that CIC suppresses 
prostate cancer progression. CIC expression was markedly decreased in human 
prostatic carcinoma. CIC overexpression suppressed prostate cancer cell proliferation, 
invasion, and migration, whereas CIC RNAi exerted opposite effects. We found 
that knock-down of CIC derepresses expression of ETV5 and CRABP1 in LNCaP and 
PC-3 cells, respectively, thereby promoting cell proliferation and invasion. We also 
discovered that miR-93, miR-106b, and miR-375, which are known to be frequently 
overexpressed in prostate cancer patients, cooperatively down-regulate CIC levels 
to promote cancer progression. Altogether, we suggest miR-93/miR-106b/miR-375-
CIC-CRABP1 as a novel key regulatory axis in prostate cancer progression.
INTRODUCTION
CIC is an HMG box-containing transcriptional 
repressor evolutionarily conserved from nematodes to 
humans [1]. CIC preferentially binds to TG/CAATGA/
GA sequences within promoters and enhancers of target 
genes in Drosophila and mammals [2], and a bacterial 
one-hybrid screen for DNA binding motifs of Drosophila 
transcription factors has revealed that the consensus 
sequence of CIC binding motifs is 5’-YYCATTSA-3’ 
[3, 4]. At least two CIC isoforms exist in Drosophila and 
mammals, CIC-L and CIC-S, which differ in their amino-
terminal regions. The longer isoform CIC-L contains 
a unique amino-terminal region of approximately 900 
amino acids in length in mammals [2]. In mammals, 
CIC was identified as an interacting protein of ATXN1, 
the causative protein of SCA1 neurodegenerative disease 
[5]. Haploinsufficiency of CIC partially rescues ataxia 
phenotypes in Atxn1154Q knock-in mice, suggesting that 
CIC facilitates pathogenesis of SCA1 [6]. It is also known 
that Cic hypomorphic (Cic-L-/-) mice have defects in lung 
alveolarization and bile acid homeostasis [7, 8].
Several previous findings have implicated that 
CIC might be involved in tumorigenesis and/or cancer 
progression in humans. First, dozens of mutations in 
CIC have been identified in patients with various types 
of cancers [9-11]. Second, a chromosomal translocation 
generating a CIC-DUX4 fusion was identified in Ewing-
like sarcomas [12]. Third, the best known target genes of 
CIC include PEA3 group genes, ETV1/ER81, ETV4/PEA3, 
and ETV5/ERM, which are frequently overexpressed in 
several different types of cancers [13, 14]. Despite the 
findings supporting the potential role of CIC in cancer, it 
has not been clear whether CIC deficiency or mutations 
indeed contribute to cancer progression. In this study, we 
show that CIC functions as a negative regulator of prostate 
cancer progression.
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RESULTS
CIC is down-regulated in prostate cancer cells
Given that several ETS transcription factor genes 
(ERG and PEA3 group genes) are frequently overexpressed 
due to chromosomal translocations in prostate cancer 
cells, thereby contributing to prostate cancer pathogenesis 
[15], we hypothesized that CIC might suppress prostate 
cancer progression through repressing expression of 
PEA3 group genes. To test this hypothesis, we first 
examined expression of CIC in mouse prostate cells by 
immunocytochemistry. We found that CIC is expressed 
in the nucleus of both basal and luminal cells of mouse 
prostate glands (Supplementary Figure 1). As a control, a 
marked decrease in fluorescence signal in thymus sections 
from Cic-L-/- mice [6, 7] compared with wild-type (WT) 
littermates verified the suitability of our antibody [8] in 
evaluating CIC expression (Supplementary Figure 2). We 
next determined patterns of CIC expression in prostate 
cancer patient specimens. Consistent with the results 
from mouse (Supplementary Figure 1), CIC is apparently 
expressed in the nuclei of both basal and luminal cells of 
non-cancerous human prostate glands (Figures 1A~1C’’’). 
Intriguingly, however, the proportion of cells with nuclear 
CIC expression was markedly decreased in prostatic 
intraepithelial neoplasia (PIN) (Figures 1D~1F’’’). 
Moreover, the nuclear expression of CIC disappeared 
in advanced prostatic adenocarcinoma with complete 
loss of basal cells (Figures 1G~1I’’’). These results were 
consistently observed in prostate tissue specimens from 
13 different prostate cancer patients (Supplementary Table 
1) and the average values for the proportion of cells with 
nuclear CIC expression in non-cancerous prostate glands, 
PIN, and prostatic adenocarcinoma are presented in Figure 
1J. Consistent with these findings, CIC protein levels were 
lower in prostate cancer cell lines than in PNT2 normal 
prostate epithelial cell (Supplementary Figure 3). Notably, 
CIC levels were the lowest in PC-3, the most aggressive 
type of prostate cancer cell [16], among the tested prostate 
cell lines (Supplementary Figure 3). Taken together, 
these data demonstrate that prostate cancer progression 
is accompanied with down-regulation of CIC expression.
CIC suppresses cell proliferation, invasion and 
migration in prostate cancer cells
We then examined whether the decrease in CIC 
levels is necessary for promotion of prostate cancer 
progression. We overexpressed CIC in PC-3 and LNCaP 
cells by infection with lentivirus expressing either 
mouse CIC-S or CIC-L (Figure 2A), and checked cell 
proliferation, invasion, and migration. Clonogenic and 
BrdU labeling assays demonstrated that overexpression 
of CIC suppresses prostate cancer cell proliferation 
(Figures 2B and Supplementary Figure 4). Moreover, 
cell invasion and migration were markedly inhibited 
in PC-3 and LNCaP cells overexpressing CIC (Figure 
2C and Supplementary Figure 5A). We also tested 
whether deficiency of CIC could promote prostate cancer 
progression. To this end, we generated prostate cancer cell 
lines that stably express three different shRNAs targeting 
CIC (shCIC-1~3). These CIC shRNAs showed different 
knock-down efficiency in each cell line: shCIC-3 most 
dramatically decreased CIC levels in PC-3, while such 
was the case for shCIC-2 in LNCaP (Figure 2D). Both 
clonogenic and BrdU labeling assays demonstrated 
that reduction in CIC levels significantly increases cell 
proliferation in PC-3 and LNCaP cells (Figure 2E and 
Supplementary Figure 6). We also found that invasive 
property of cells was markedly enhanced by knock-down 
of CIC in both LNCaP and PC-3 cells (Figure 2F) and 
that cell migration was significantly increased in the CIC 
knock-down PC-3 cells (Supplementary Figure 5B). The 
increases in cell proliferation, invasion, and migration 
were apparently correlated with CIC knock-down 
efficiency, suggesting that these results were certainly 
due to a decrease in CIC levels and not owing to the 
off-target effect of CIC shRNAs. Taken together, these 
data demonstrate that CIC could function as a negative 
regulator in prostate cancer progression.
Derepression of ETV5 contributes to the increases 
in cell proliferation and invasion in the CIC 
knock-down LNCaP cells
Given that PEA3 group genes are regulated by CIC 
and that altered expression of these genes is associated 
with the pathogenesis of various types of cancers 
including prostate cancer [17], we assessed levels of 
PEA3 group genes in the CIC knock-down cell lines by 
qRT-PCR. Significant up-regulation of ETV5 levels was 
found in CIC knock-down LNCaP cells (Figure 3A), while 
unexpectedly, levels of ETV1, ETV4, and ETV5 were 
comparable among control and CIC knock-down PC-3 
cell lines (Supplementary Figure 7), suggesting a cell-type 
specific regulation of PEA3 group genes by CIC. We then 
examined whether the derepression of ETV5 contributed 
to promotion of cell proliferation and invasion in the CIC 
knock-down LNCaP cells. We treated the shCIC-1 and 
shCIC-2 LNCaP cells with siRNA against ETV5 (siETV5) 
to make the level of ETV5 similar to that in control cells 
(Figure 3B), and assessed cell proliferation and invasion. 
The RNAi against ETV5 significantly suppressed cell 
proliferation and invasion in the CIC knock-down LNCaP 
cells (Figures 3C and 3D and Supplementary Figure 8), 
indicating that ETV5 is a critical target of CIC in LNCaP 
cells in terms of regulation of cancer progression. 
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Figure 1: Decreased nuclear expression of CIC in prostate cancer cells. A.-C.’’’ Immunocytochemistry for CIC, keratin 8 (K8, 
luminal cell marker), and keratin 5 (K5, basal cell marker) in prostate cancer patient specimens. CIC is markedly expressed in the nucleus 
of non-cancerous prostate glands. Arrows and arrow heads indicate luminal and basal cells, respectively. Images were taken from the 
specimen of patient #3. D.-F.’’’ Expression patterns of CIC in prostatic intraepithelial neoplasia (PIN). The number of cells with the nuclear 
expression of CIC was apparently reduced in PIN compared with the non-cancerous prostate glands. Arrows and arrow heads indicate 
luminal and basal cells, respectively. Images were taken from the specimen of patient #3. G.-I.’’’ Absence of nuclear expression of CIC 
in prostatic adenocarcinoma. Images were taken from the specimen of patient #2. J. Quantitative analysis for the proportion of cells with 
nuclear expression of CIC in non-cancerous prostate glands, PIN, and prostatic adenocarcinoma. Four to seven regions of non-cancerous 
prostate glands, PIN, and prostatic adenocarcinoma per each specimen were randomly selected from all the tested patient samples, and the 
proportion of nuclear CIC signal-positive cells was examined. ***P < 0.001. All error bars show s.e.m.
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Overexpression of CRABP1 contributes to the 
increases in cell proliferation and invasion in the 
CIC knock-down PC-3 cells
Given the comparable expression of PEA3 group 
genes in control and CIC knock-down PC-3 cells 
(Supplementary Figure 7), we investigated which gene 
expression changes upon knock-down of CIC promoted 
cell proliferation and invasion in PC-3 cells. To this end, 
we analyzed gene expression profiles in control and CIC 
knock-down (shCIC-3) PC-3 cells. The high throughput 
mRNA sequencing analysis revealed that a total of 262 
genes (159 up-regulated, and 103 down-regulated) was 
differentially expressed (Fold change (log2) > 2 and 
P-value < 0.05) in the shCIC-3 PC-3 cells compared 
Figure 2: CIC suppresses cell proliferation and invasion in PC-3 cells. A. Western blot analysis for ectopic expression of 
CIC-S and CIC-L in PC-3 and LNCaP cells. B. Clonogenic assay showing inhibition of cell growth by overexpression of CIC in PC-3 and 
LNCaP cells. The right panel is a bar graph for quantitative analysis on colony numbers. Three independent experiments were performed. 
***P < 0.001. All error bars show s.e.m. C. Matrigel invasion assay showing inhibition of cell invasion by overexpression of CIC in PC-3 
and LNCaP cells. The right panel is a bar graph for quantitative analysis on invasive cell numbers. Three independent experiments were 
performed. ***P < 0.001. All error bars show s.e.m. D. Western blot analysis to examine CIC knock-down efficiency of three different 
shRNAs against CIC (shCIC-1~3) in PC-3 and LNCaP cells. Relative CIC levels were calculated based on band intensities of CIC and 
β-actin, and indicated below the images. Two and three independently obtained western blot images for samples of PC-3 and LNCaP cells, 
respectively, were subjected to the quantitative analysis for the relative CIC levels. E. Clonogenic assay showing promotion of cell growth 
by knock-down of CIC in PC-3 and LNCaP cells and its quantification. Three independent experiments were performed. *P < 0.05, **P < 
0.01 and ***P < 0.001. All error bars show s.e.m. F. Matrigel invasion assay showing promotion of cell invasion by knock-down of CIC 
in PC-3 and LNCaP cells and its quantification. Three independent experiments were performed. **P < 0.01 and ***P < 0.001. All error 
bars show s.e.m.
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with control cells (Supplementary Table 2). Among 
the differentially expressed genes, cellular retinoic 
acid binding protein 1 (CRABP1) primarily caught our 
attention, because of the highest fold increase upon knock-
down of CIC in PC-3 cells (Supplementary Table 2) and 
its previously known pro-tumorigenic and pro-metastatic 
activity in mesenchymal tumors [18]. Moreover, it is 
known that CRABP1 is overexpressed in castration-
resistant prostate cancer cells [19]. Consistent with this, 
we observed that CRABP1 levels are much higher in PC-3 
cells, which are independent of androgen for their growth 
[16], than in LNCaP and PNT2 cells (Supplementary 
Figure 9). We confirmed the overexpression of CRABP1 
at protein level in the CIC knock-down PC-3 cells 
by western blot analysis (Figure 4A). To verify that 
the overexpression of CRABP1 was certainly due to 
deficiency of CIC, we carried out RNAi against CIC in 
PC-3 cells using siRNA duplexes (siCIC) and examined 
the expression of CRABP1 by qRT-PCR. The treatment 
with siCIC also up-regulated CRABP1 levels in PC-3 cells 
(Supplementary Figure 10), suggesting that CIC indeed 
negatively regulates CRABP1 expression. On the other 
hand, we found that CRABP1 levels were not significantly 
altered in CIC knock-down LNCaP cells (Supplementary 
Figure 11), indicating that CIC regulates CRABP1 
expression in a cell-type dependent manner. 
We then explored whether CRABP1 could regulate 
cell proliferation and invasion in prostate cancer cells. 
Lentivirus-mediated overexpression of FLAG-CRABP1 
increased cell proliferation as well as invasion in PC-3 
cells (Figures 4B and 4C and Supplementary Figure 
12), suggesting that CRABP1 can function as a positive 
regulator of prostate cancer progression. Finally, we 
examined whether the up-regulation of CRABP1 levels 
contributed to the increased cell proliferation and invasion 
in the CIC knock-down PC-3 cells. We carried out RNAi 
against CRABP1 using two different CRABP1 siRNAs 
(siCRABP1-1 and siCRABP1-2) in the CIC knock-down 
PC-3 cells to make the level of CRABP1 comparable to 
that in control cells (Figure 4D). Under this condition, we 
performed clonogenic, cell growth, and invasion assays, 
and found that transfection with CRABP1 siRNAs reduced 
cell proliferation and invasion in the CIC knock-down 
PC-3 cells (Figures 4E and 4F and Supplementary Figure 
13), demonstrating that the increase in CRABP1 levels 
contributed to the promotion of cancer progression in the 
CIC knock-down PC-3 cells. 
CRABP1 is a direct target gene of CIC in PC-3 
cells
We next set out to determine the molecular basis 
of CRABP1 overexpression by CIC deficiency. Given 
that CIC functions as a transcriptional repressor and that 
the levels of CRABP1 are increased by CIC deficiency, 
we hypothesized that CRABP1 might be a target gene 
Figure 3: Derepression of ETV5 contributes to the increased cell proliferation and invasion in CIC knock-down LNCaP 
cells. A. qRT-PCR analysis for ETV1, ETV4 and ETV5 levels in the CIC knock-down LNCaP cells. Three independent experiments were 
performed. *P < 0.05 and **P < 0.01. All error bars show s.e.m. B. qRT-PCR analysis for ETV5 levels in the CIC knock-down LNCaP cells 
transfected with either control or ETV5 siRNA. Three independent experiments were performed. *P < 0.05 and **P < 0.01. All error bars 
show s.e.m. C. Clonogenic assay using control, shCIC-1 and shCIC-2 LNCaP cells treated with either control or ETV5 siRNA. Suppression 
of ETV5 expression reduced colony formation in the shCIC-1 and shCIC-2 LNCaP cells. The lower panel is a bar graph for quantitative 
analysis on colony numbers. Three independent experiments were performed. ***P < 0.001. All error bars show s.e.m. D. Matrigel invasion 
assay using control, shCIC-1 and shCIC-2 LNCaP cell lines treated with either control or ETV5 siRNA. Suppression of ETV5 expression 
reduced the number of invasive cells. The lower panel is a bar graph for quantitative analysis on invasive cell numbers. Three independent 
experiments were performed. ***P < 0.001. All error bars show s.e.m.
Oncotarget23538www.impactjournals.com/oncotarget
of CIC. To test this hypothesis, we first searched for 
CIC binding motifs in CRABP1 promoter region and 
found a putative CIC binding motif within 3kb region 
upstream from the transcriptional start site of CRABP1 
(Supplementary Figure 14). We then examined whether 
CIC binds to the CRABP1 promoter region containing the 
CIC binding motif. To this end, we carried out chromatin 
immunoprecipitation (ChIP) using anti-FLAG antibody 
in PC-3 cells expressing FLAG-CIC-S followed by 
qPCR for CRABP1 promoter regions. The ChIP-qPCR 
analyses indicate that DNA fragments corresponding to 
the CRABP1 promoter region with the CIC binding motif 
are significantly enriched in the immunoprecipitates of 
FLAG-CIC-S (Figure 5A), suggesting that CIC might 
repress CRABP1 expression through a direct binding 
to the promoter region in PC-3 cells. To determine 
that CIC indeed represses CRABP1 promoter activity, 
we generated luciferase expression vector driven by 
CRABP1 promoter (pGL3-CRABP1 pro) and carried out 
dual luciferase assay using this reporter construct. When 
CIC-S and ATXN1, the latter of which has been known to 
enhance the transcriptional repressor activity of CIC [5, 
20], were co-expressed in PC-3 cells, luciferase activity 
was significantly decreased, indicating suppression of 
CRABP1 promoter activity by CIC (Figure 5B). Moreover, 
mutagenesis at the putative CIC binding motif abolished 
the suppressive effect of CIC on CRABP1 promoter 
activity (Figure 5B), demonstrating that CIC represses 
transcription of CRABP1 through the CIC binding motif. 
Taken together, our data indicate that CRABP1 expression 
is directly regulated by CIC in PC-3 cells.
miR-93, miR-106b, and miR-375 cooperatively 
down-regulate CIC levels
Since CIC levels were markedly decreased in 
prostate cancer cells, we set out to identify a potential 
underlying mechanism. It is known that several 
microRNAs (miRNAs) are abnormally expressed in 
prostate cancer cells [21, 22], implicating their potential 
roles in tumorigenesis and/or cancer progression. In this 
regard, it would be conceivable that overexpression of 
a subset of miRNAs targeting CIC might down-regulate 
Figure 4: Overexpression of CRABP1 promotes cancer progression in CIC knock-down PC-3 cells. A. Western blot 
analysis for endogenous CRABP1 expression in control and CIC knock-down PC-3 cell lines. B. Western blot analysis for ectopic 
expression of FLAG-CRABP1 in PC-3 cells. C. Clonogenic and matrigel invasion assays showing promotion of cell growth and invasion, 
respectively, by overexpression of CRABP1 in PC-3 cells, and its quantification. Three clonogenic assays and five matrigel invasion assays 
were performed independently. ***P < 0.001. All error bars show s.e.m. D. qRT-PCR analysis for CRABP1 levels to check suppression of 
CRABP1 expression by siRNAs against CRABP1 (siCRABP1-1 and siCRABP1-2) in control and CIC knock-down PC-3 cell lines. Seven 
independent experiments were performed. *P < 0.05 and **P < 0.01. All error bars show s.e.m. E. Clonogenic assay using control and CIC 
knock-down PC-3 cell lines treated with two different CRABP1 siRNAs. Suppression of CRABP1 expression reduced colony formation 
in the CIC knock-down PC-3 cell lines. The right panel is a bar graph for quantitative analysis on colony numbers. Four independent 
experiments were performed. ***P < 0.001. All error bars show s.e.m. F. Matrigel invasion assay using control and CIC knock-down PC-3 
cell lines treated with two different CRABP1 siRNAs. Suppression of CRABP1 expression reduces the number of invasive cells. The right 
panel is a bar graph for quantitative analysis on invasive cell numbers. Three independent experiments were performed. ***P < 0.001. All 
error bars show s.e.m.
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CIC levels to promote cancer progression in the prostate. 
Thus, we sought to identify miRNAs targeting CIC among 
the miRNAs known to be overexpressed in patients with 
prostate cancer. Based on previous work [21, 23-27], 
we searched for miRNAs that have been reported to be 
up-regulated in samples from prostate cancer patients 
by at least two independent studies. We also looked for 
miRNAs potentially targeting CIC using miRNA target 
prediction databases [28, 29]. Comparative analysis on 
the selected miRNAs identified five miRNAs, miR-20a, 
miR-25, miR-93, miR-106b, and miR-375, which not only 
potentially target CIC, but are also known to be frequently 
overexpressed in prostate cancer cells (Supplementary 
Figure 15A). Since the seed sequences of miR-20a, miR-
93, and miR-106b are identical, they are classified as the 
same miRNA family (miR-17 family). There are two 
putative binding sites for miR-20a/miR-93/miR-106b, one 
for miR-25 and another for miR-375 in the 3’UTR of CIC 
(Supplementary Figure 15B). Of the five miRNAs, we 
initially chose to evaluate miR-93, miR-106b, and miR-
375, considering the number of putative binding sites for 
each miRNA in the 3’UTR of CIC and their frequency 
of overexpression in prostate cancer patients, and tested 
whether these miRNAs can down-regulate CIC levels. 
Transfection with each individual miRNA duplex did not 
significantly affect CIC levels in PC-3 cells (Figures 6A 
and 6C). However, co-transfection with all three miRNA 
duplexes markedly down-regulated CIC levels in PC-3 
cells (Figures 6B and 6C), indicating that miR-93, miR-
106b, and miR-375 cooperatively regulate CIC levels. We 
did not observe such effect when different combinations 
of two miRNA duplexes were co-transfected (Figure 6B), 
suggesting that miR-93 and miR-106b may not function 
redundantly to regulate CIC levels, although they share the 
same seed sequences. In fact, among the two putative miR-
17 family miRNA binding sites in the CIC 3’UTR, the 
first site is predicted to be more preferentially targeted by 
miR-93, whereas the second one by miR-106b, according 
to the miRNA target prediction databases (Supplementary 
Figure 15B). Moreover, it has been known that nucleotide 
sequences outside of seed sequences also contribute 
to determination of target mRNA binding specificity 
of miRNAs [30, 31]. We also examined whether CIC 
expression is regulated by endogenous miR-93, miR-106b, 
and miR-375 in PC-3 cells. Inhibition of miR-375, but not 
miR-93 and miR-106b, significantly increased CIC levels 
Figure 5: CRABP1 is a direct target of CIC in PC-3 cells. A. ChIP-qPCR analyses for CIC occupancy of CRABP1 promoter 
in PC-3 cells. PC-3 cells infected with control or FLAG-CIC-S expressing lentivirus were subjected to ChIP using anti-FLAG antibody 
followed by qPCR for CRABP1 promoter regions. The left panel is schematic illustration showing the loci of the putative CIC binding motif 
(asterisk) and PCR amplified regions (R1 and R2) within 3kb region upstream from the CRABP1 transcriptional start site. Four independent 
experiments were performed. **P < 0.01. All error bars show s.e.m. B. Luciferase assay showing that CIC represses CRABP1 promoter 
activity through the CIC binding motif in CRABP1 promoter. The left panel is a schematic illustration for the luciferase reporter construct 
harboring the CRABP1 promoter region (pGL3-CRABP1 pro) and mutated sequences of the putative CIC binding motif. Four independent 
experiments were performed. **P < 0.01. All error bars show s.e.m.
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(Figure 6D), suggesting that, among the three miRNAs, 
miR-375 is the most critical endogenous miRNA for 
regulation of CIC levels in PC-3 cells. To verify that miR-
93, miR-106b, and miR-375 directly target the 3’UTR of 
CIC, we constructed luciferase reporter gene linked to 
the CIC 3’UTR (pGL3-CIC 3’UTR WT), and carried out 
dual luciferase assays. Co-transfection with three miRNAs 
decreased luciferase activity in PC-3 cells (Figure 6E), 
suggesting that miR-93, miR-106b, and miR-375 down-
regulate CIC levels through the 3’UTR of CIC. Moreover, 
disruption of the putative miRNA binding sites in the 
3’UTR of CIC abrogated suppression of luciferase activity 
by the three miRNAs (Figure 6E), demonstrating that miR-
93, miR-106b, and miR-375 directly target the 3’UTR of 
CIC to regulate CIC levels. On the other hand, the three 
miRNAs still slightly repressed luciferase activity derived 
from the pGL3-CIC 3’UTR Mut compared with control 
vector (Figure 6E), implying that there might be other 
binding sites for miR-93, miR-106b, and miR-375 in the 
3’UTR of CIC, or that the three miRNAs might also be 
able to repress CIC expression indirectly. 
miR-93, miR-106b, and miR-375 cooperatively 
regulate CIC-CRABP1 axis to promote prostate 
cancer progression
To determine the impact of the miRNAs-mediated 
down-regulation of CIC on prostate cancer progression, 
we assessed cell proliferation and invasion in PC-3 
cells transfected with either control, miR-93/miR-106b/
miR-375 or siCIC duplexes. Overexpression of miR-93, 
miR-106b, and miR-375 increased cell proliferation and 
invasion (Figures 7B and 7C and Supplementary Figure 
16), accompanied with down-regulation of CIC levels 
(Figure 7A), suggesting the cancer promoting property 
of these three miRNAs in prostate cancer cells. To verify 
Figure 6: miR-93, miR-106b, and miR-375 cooperatively down-regulate CIC levels in PC-3 cells. A. Western blot analysis 
for CIC levels in PC-3 cells transfected with control, miR-93, miR-106b, or miR-375 duplexes. B. Western blot analysis for changes in CIC 
levels by overexpression of miR-93, miR-106b, and miR-375 in PC-3 cells. Co-expression of three miRNAs significantly decreased levels 
of CIC. C. Bar graph for quantitative analysis on the level of CIC based on western blot images. More than three independent experiments 
were carried out. ***P < 0.001. All error bars show s.e.m. D. Western blot analysis for changes in CIC levels by inhibition of endogenous 
miR-93, miR-106b or miR-375 in PC-3 cells and its quantification. Inhibition of miR-375 significantly increased levels of CIC. More than 
three independent experiments were carried out. ***P < 0.001. All error bars show s.e.m. E. Luciferase assay showing that the 3’UTR 
of CIC is responsible for the miRNAs-mediated down-regulation of CIC expression in PC-3 cells. Three independent experiments were 
carried out. *P < 0.05. All error bars show s.e.m.
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that the miRNAs-mediated down-regulation of CIC levels 
contributed to the enhanced cell proliferation and invasion, 
we restored CIC levels in PC-3 cells co-transfected with 
the three miRNA duplexes by mouse CIC-S expressing 
lentiviral infection (Figure 7A), and conducted clonogenic, 
cell growth, and invasion assays. The miRNAs-mediated 
increases in cell proliferation and invasion were partially 
abolished by recovery of CIC levels in PC-3 cells (Figures 
7B and 7C and Supplementary Figure 16), suggesting that 
miR-93, miR-106b, and miR-375 promote prostate cancer 
progression in part by down-regulation of CIC expression. 
We also measured CRABP1 levels in the same set of cells, 
and found that co-expression of miR-93, miR-106b, and 
miR-375 resulted in up-regulation of CRABP1, which 
was restored by overexpression of CIC in PC-3 cells 
(Figure 7D). Taken together, these data demonstrate that 
miR-93, miR-106b, and miR-375 function cooperatively 
to regulate the CIC-CRABP1 axis in promoting prostate 
cancer progression.
DISCUSSION
Our study demonstrates that CIC negatively 
regulates prostate cancer progression and raises a 
possibility that CIC could be a novel tumor suppressor for 
prostate cancer. According to The Cancer Genome Atlas 
(TCGA, http://cancergenome.nih.gov/), the frequencies 
of deletional and truncating CIC gene mutations found 
in 258 prostate cancer patient samples are 3.1% (8 cases) 
and 0.4% (1 case), respectively. Examination of how those 
mutations affect the activity of CIC would be critical 
to further evaluate the potential role of CIC as a tumor 
suppressor in the prostate. 
In this study, we identified CRABP1 as a novel 
CIC target, and provided a molecular basis of how CIC 
regulates prostate cancer progression. Although a few 
Figure 7: miR-93, miR-106b, and miR-375 co-regulate CIC-CRABP1 axis to promote cancer progression in PC-3 cells. 
A. Western blot analysis for CIC levels in PC-3 cells treated with different combinations of three miRNA duplexes or siCIC, and control 
or CIC-S-expressing lentivirus. B. Clonogenic assay for the PC-3 cells used in A. and its quantification. Three independent experiments 
were carried out. **P < 0.01 and ***P < 0.001. All error bars show s.e.m. C. Matrigel invasion assay for the PC-3 cells used in A. and its 
quantification. Three independent experiments were carried out. ***P < 0.001. All error bars show s.e.m. D. qRT-PCR analysis for CRABP1 
levels in the PC-3 cells used in A.. Three independent experiments were carried out. *P < 0.05, **P < 0.01 and ***P < 0.001. All error 
bars show s.e.m. E. The proposed model that describes how prostate cancer progression is regulated by miRNAs, CIC, and its target genes, 
based on the findings in this study. The question marks mean unidentified factors or mechanisms.
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studies have shown that CRABP1 could promote cancer 
progression in some types of cancer [18, 32], we now for 
the first time show that CRABP1 has cancer promoting 
property in prostate cancer cells. However, it remains 
unknown how CRABP1 facilitates cell proliferation and 
invasion in prostate cancer cells. In fact, the binding 
of retinoic acid, which stimulates differentiation and 
inhibits proliferation of cells, is the only known function 
of CRABP1 [33]. On the other hand, it has also been 
reported that the cancer promoting activity of CRABP1 
is independent of the retinoic acid binding activity 
[18]. Therefore, in-depth molecular characterization 
of CRABP1 will be required for understanding of the 
molecular mechanism underlying the promotion of 
prostate cancer progression by CRABP1. 
We found that CIC represses expression of ETV5 
and CRABP1 in a cell-type dependent manner. This 
conclusion is further supported by our findings that 
expression of ETV5 and CRABP1 is not up-regulated by 
knock-down of CIC in DU145 cells whereas levels of 
ETV5, but not CRABP1, are significantly up-regulated 
in CIC knock-down LNCaP-LN3 cells (Supplementary 
Figure 17). Given that PC-3 cells are highly metastatic 
and independent of androgen [16], the CIC-CRABP1 axis 
might play a critical role in regulation of prostate cancer 
progression at metastatic and castration-resistant stages. 
The mRNA sequencing analysis also reveals that several 
genes, such as NUDT11, CCNA1, and HNF1B, known 
to promote prostate cancer progression [34, 35], are 
significantly up-regulated in the CIC knock-down PC-3 
cells (Supplementary Table 2). In fact, knock-down of CIC 
more dramatically increased cell proliferation and invasion 
in PC-3 cells than overexpression of CRABP1 (Figures 2E, 
2F and 4C), suggesting that not only CRABP1, but other 
genes regulated by CIC are also involved in promotion 
of cancer progression by CIC deficiency. Identification of 
CIC target genes and elucidation of CIC-mediated gene 
expression regulatory networks at different stages of 
prostate cancer pathogenesis will uncover CIC-mediated 
molecular pathways regulating cancer progression in the 
prostate. 
Our data indicate that CIC levels are drastically 
decreased in prostatic carcinoma. We consistently 
observed disappearance of the nuclear CIC expression 
in prostatic adenocarcinoma in all of the tested patient 
specimens. Moreover, overexpression of CIC markedly 
suppressed cell proliferation, invasion, and migration 
in PC-3 cells. Therefore, CIC could be considered as 
a therapeutic target as well as a molecular marker of 
prostate cancer. We identified miRNAs targeting CIC 
from the miRNAs known to be overexpressed in prostate 
cancer tissues, and proposed that miR-93, miR-106b, 
and miR-375 could potentially contribute to the down-
regulation of CIC levels in the process of prostate cancer 
progression. Comparative miRNA profiling of prostate 
carcinomas with increasing tumor stages has revealed 
that levels of miR-375 and miR-106b gradually increase 
from normal to lymph node metastasizing tumors, whereas 
miR-93 increases from normal to extracapsular growing 
tumors [36], suggesting that these miRNAs are likely to 
participate in the gradual decrease in CIC levels during 
prostate cancer progression.
In sum, our findings suggest that miR-93/miR-
106b/miR-375-CIC-CRABP1 is a novel regulatory axis 
in prostate cancer progression (Figure 7E). Identification 
of other components involved in this regulatory axis and 
further studies on their functions will not only advance the 
understanding of pathogenesis of prostate cancer, but may 
also uncover novel therapeutic targets that can be used in 
the design of treatment modalities for prostate cancer.
MATERIALS AND METHODS
Human tissue samples
This study was approved by the Asan Medical 
Center Institutional Review Board (2011-499). Patients 
who underwent radical prostatectomy between January 
2006 and December 2012 at Asan Medical Center were 
selected. We randomly chose 13 prostate cancer patients’ 
tissues to detect CIC expression by immunofluorescence 
staining. According to the value of the Gleason score, the 
patient’s samples were divided into patients with Gleason 
score with 5-9. 
Immunofluorescence staining
Immunofluorescence staining was performed 
using standard protocols. Briefly, paraffin sections were 
dewaxed using xylene for 30 min, and antigen retrieval 
was performed by boiling in 10mM sodium citrate for 
15 min. The sections were treated with rabbit anti-CIC 
[8] (1:100), chicken anti-Keratin 5 (1:100) (COVANCE, 
Hertfordshire, England), mouse anti-Cytokeratin 8 
(1:500) (COVANCE, Hertfordshire, England), or mouse 
anti-Cytokeratin 14 (1:100) (BioGenex, CA, USA) 
antibodies overnight at 4°C, and then incubated with 
secondary antibodies, Alexa Fluor 488 goat anti-rabbit 
IgG (Invitrogen, NY, USA), Alexa Fluor 594 goat anti- 
mouse IgG (Invitrogen, NY, USA) and goat anti-chicken 
IgY-TR (Santa Cruz Biotechnology, TX, USA) for 1 h 
at room temperature with 4,6-diamidino-2-phenylindole 
(DAPI) (Sigma-Aldrich, MO, USA). Immunofluorescence 
staining was imaged using ZEISS Axioplan2 fluorescence 
microscope or ZEISS LSM700 confocal microscope. 
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Cell culture
PNT2, PC-3, LNCaP, DU145 and LNCaP-LN3 
cells were maintained in RPMI 1640 (HyClone, UT, 
USA) with 10% fetal bovine serum (FBS) and 1% 
penicillin/streptomycin (WELGENE, Daegu, Republic of 
Korea). All cell lines were maintained at 37℃ in a humid 
atmosphere containing 5% CO2. Instead of trypsin, cell 
scrapers were used to detach PC-3 cells during subculture 
of the cells.
Transfection of siRNA and miRNA duplexes and 
miRNA inhibitor
miRNA inhibitors, miRNA mimic duplexes, 
and siRNAs targeting CRABP1, CIC, and ETV5 
were purchased from Bioneer (Daejun, Republic of 
Korea). Sequences are as follows: miR-93 sense; 
5’-CAAAGUGCUGUUCGUGCAGGUAG-3’, and 
antisense; 5’-ACCUGCACGAACAGCACUUUAUU-3’. 
miR-106b sense; 
5’-UAAAGUGCUGACAGUGCAGAU-3’, and antisense; 
5’-CUGCACUGUCAGCACUUUGUU-3’. miR-375 
sense; 5’-UUUGUUCGUUCGGCUCGCGUGA-3’, and 
antisense; 5’-ACGCGAGCCGAACGAACAAAUU-3’. 
siETV5 sense; 5’-CACAAGCUUAGAUUCUCUA-3’, 
and antisense; 5’- UAGAGAAUCUAAGCUUGUG-3’. 
siCIC sense; 5’-CAGAACGGCUACACACAGU-3’, 
and antisense; 5’-ACUGUGUGUAGCCGUUCUG-3’. 
siCRABP1-1 sense; 
5’-GUAUCCCUAGUGCUCCAUA-3’, and antisense; 
5’-UAUGGAGCACUAGGGAUAC-3’. siCRABP1-2 
sense; 5’-CGAAGUCAUUAAACUGGUU-3’, and 
antisense; 5’-AACCAGUUUAAUGACUUCG-3’. 
Transfection of siRNA duplexes, miRNA duplexes, or 
miRNA inhibitors was conducted using Dharmafect 2 
(Dharmcon, CO, USA) according to the manufacturer’s 
instructions. The cells were transfected with 120 pmole 
of siRNA duplexes or 60 pmole of miRNA inhibitors, and 
incubated for 72~96 h.
Clonogenic assay
For clonogenic assay of CIC knock-down PC-3 or 
LNCaP cells, 2 × 103 or 4 × 10
3
 cells were seeded in six 
well plates and incubated for 7~8 days or 14~15 days, 
respectively. For clonogenic assay of PC-3 or LNCaP cells 
overexpressing CIC, 2 × 103 or 4 × 103 cells were seeded 
in six well plates and incubated for 14~15 days or 10~11 
days, respectively. For clonogenic assay of PC-3 cells 
overexpressing FLAG-CRABP1, 2 × 103 cells were seeded 
in six well plates and incubated for 5 days. The cells were 
stained with formalin/0.1% crystal violet solution. For 
clonogenic assay of siRNAs-treated CIC knock-down 
PC-3 or LNCaP cells, 2 × 103 or 4 × 10
3
 cells were seeded 
in six well plates a day before transfection, respectively, 
and then siRNAs were transfected using Dhamafect 2. 
The cells were stained with formalin/0.1% crystal violet 
solution after 72 h incubation. For clonogenic assay 
of PC-3 cells treated with miRNA duplexes and CIC-S 
expressing lentivirus, 5 × 103 PC-3 cells were seeded 
in six well plates a day before transfection, and then 
co-transfected with miR-93, miR-106b, and miR-375 
duplexes using Dhamafect 2. After 24 h, the cells were 
infected with lentivirus expressing CIC-S for 3 sequential 
days. The cells were stained with formalin/0.1% crystal 
violet solution and analyzed using Olympus CKX41 
microscope and Adobe Photoshop CS6 software. Analyzed 
cell number is listed in Table S3.
Cell growth assay
For cell growth assay of PC-3 cells overexpressing 
FLAG-CRABP1, 1 × 103 cells were seeded in 24 well 
plates and incubated for 6 days. The cells were trypsinized, 
stained with Trypan Blue (Sigma-Aldrich, MO, USA), 
and counted for the number of viable cells using 
hemacytometer. For cell growth assay of siRNAs-treated 
CIC knock-down PC-3 or LNCaP cells, 1 × 103 cells were 
seeded in 24 well plates a day before transfection, and then 
siRNAs were transfected using Dhamafect 2 and set as day 
“0”. The cells were trypsinized, stained with Trypan Blue 
(Sigma-Aldrich, MO, USA), and counted for the number 
of viable cells using hemacytometer every other day for 
6 days. For cell growth assay of PC-3 cells treated with 
miRNA duplexes and CIC-S expressing lentivirus, 1 × 
103 PC-3 cells were seeded in 24 well plates a day before 
transfection, and then co-transfected with miR-93, miR-
106b, and miR-375 duplexes using Dhamafect 2 and set as 
day “0”. After 24 h, the cells were infected with lentivirus 
expressing CIC-S for 3 sequential days. The cells were 
trypsinized, stained with Trypan Blue (Sigma-Aldrich, 
MO, USA), and counted for the number of viable cells 
using hemacytometer over 4 days. 
Invasion assay
For invasion assay of CIC knock-down PC-3 or 
LNCaP cells, 5 × 103 cells were suspended in serum-
free medium and seeded into the inserts of a 24-well 
BioCoat Matrigel Invasion Chamber (BD falcon, CA, 
USA). For invasion assay of PC-3 or LNCaP cells 
overexpressing CIC, 1 ×104 or 4 × 103 cells were seeded 
into the inserts, respectively. For invasion assay of PC-3 
cells overexpressing CRABP1, 5 × 103 cells were seeded 
into the inserts. For invasion assay of siRNAs-treated CIC 
knock-down PC-3 or LNCaP cells, 2 × 103 or 3 × 10
3
 cells 
were seeded into the inserts, respectively. For invasion 
assay of PC-3 cells treated with miRNA duplexes and 
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CIC-S expressing lentivirus, 2 × 103 cells were seeded 
into the inserts. The inserts were co-cultured in a well of 
10% FBS-containing media and incubated for 24h. Inserts 
were then removed and the upper surface of the membrane 
was rubbed off to remove non-migrating cells with 
cotton swabs and washed with PBS. Then, inserts were 
stained with formalin/0.1% crystal violet solution and 
analyzed under ZEISS Axioplan2 microscope. Multiple 
15~20 images per insert were acquired, and average 
counts were calculated. Analyzed cell number is listed in 
Supplementary Table 3.
Wound healing assay
For the wound-healing assay, cells were seeded 
into 6-well plates and cultured at full confluency. A sterile 
1ml pipette tip was used to scratch the cells to form a 
wound. The cells were washed with PBS and cultured in 
serum-free medium. Wound closure was visualized with 
ZEISS AxioCamICc1 microscope. Multiple 9 images per 
well were acquired and average counts were calculated. 
Analyzed cell number is listed in Supplementary Table 3.
BrdU labeling assay
For BrdU labeling assay of CIC knock-down PC-3 
or LNCaP cells, 2 × 103 or 4 × 10
3
 cells were seeded in six 
well plates and incubated for 7~8 days and 14~15 days, 
respectively. For BrdU labeling assay of PC-3 or LNCaP 
cells overexpressing CIC, 2 × 103 or 6 × 103 cells were 
seeded in six well plates and incubated for 14~15 days, 
respectively. BrdU (Sigma-Aldrich, MO, USA) was added 
in cell culture media to a final concentration of 100mM 
and incubated for 2 h at 37℃ with 5% CO2. The cells were 
fixed with 4% paraformaldehyde, incubated with mouse 
anti-BrdU (1:200) (DSHB, Iowa, USA) overnight at 
4°C, and then with Alexa Fluro 594 goat anti-mouse IgG 
(Invitrogen, NY, USA).
Cloning
To construct pGL3-CIC 3’UTR, entire human CIC 
3’UTR sequences (606nt) were amplified from cDNA 
of MCF7 cells using Pfu-X DNA polymerase (SolGent, 
Daejun, Republic of Korea) and cloned into the pGL3-
control vector (Promega, WI, USA). To construct pGL3-
CRABP1 pro, human CRABP1 promoter region (-1927bp 
~ +2bp) was amplified from MCF7 genomic DNA using 
Pfu-X DNA polymerase and cloned into the pGL3-basic 
vector (Promega, WI, USA). To make pHAGE-FLAG-
CIC-S, and CIC-L, mouse Cic-S and Cic-L coding 
sequences were amplified from cDNA of NIH3T3 
cells using Pfu-X DNA polymerase and cloned into the 
pHAGE-FLAG lentiviral vector. To make pHAGE-
FLAG-CRABP1, human CRABP1 coding sequences were 
amplified from cDNA of MCF7 cells using Pfu-X DNA 
polymerase and cloned into the pHAGE-FLAG lentiviral 
vector.
Site-directed mutagenesis
Site-directed mutagenesis was performed using 
QuickChange II XL Site-Directed Mutagenesis kit (Agilent 
Technologies, CA, USA) according to the manufacturer’s 
instructions. The primers used for mutagenesis at miR-
93, miR-106b, and miR-375 binding sites within the 
CIC 3’UTR are as follows: 93-106b mut-1sense;5’-GT
GGGGGCTCCTGCGTCTTGCCACAGGCACGGGG
AGGGTT -3’, 93-106b mut-1 antisense; 5’- AACCCT 
CCCCGCCTGTGGCAAGACGCAGGAGCCCCCAC 
- 3’, 93-106b mut-2 sense;5’GTGACCTTCA
GAGCTTTTCGTCTTATGCAAAATGGCTC
CT-3’, 93-106b mut-2 antisense; 5‘- AGGAGC 
CATTTTGCATAAGACGAAAAGCTCTGAAGGTCAC 
- 3’, 375 mutsense;5’-CTTGCCCCCTTCCCCAGATGT
AAACATGTTGATCATGTGC-3’, and 375 mut antisense; 
TCAACATGTTTACATCTGGGGAAGGGGGCAAG-3’.
The primers used for mutagenesis at the CIC binding 
motif within CRABP1 promoter are as follows: sense;5’-
GGGTTAATCAAATCTTGCCCACCCACGAAAGCC
CATCTTTATGC-3’, antisense; 5’- GCATAAAGATGG 
GCTTTCGTGGGTGGGCAAGATTTGATTAACCC-3’.
Dual luciferase assay
To examine the effect of miRNAs on the 3’UTR of 
CIC, PC-3 cells seeded in 24-well plates were transfected 
with pGL3-control, CIC 3’UTR WT or CIC 3’UTR Mut 
(60ng), together with pRL-TK (15ng), and control or 
miRNA duplexes using Lipofectamine2000 (Invitrogen, 
NY, USA) according to the manufacturer’s instruction. To 
examine the effect of CIC and ATXN1 on the CRABP1 
promoter activity, PC-3 cells seeded in 24-well plates were 
transfected with pGL3-CRABP1 pro WT or Mut (120ng), 
together with pRL-TK (30ng), pHAGE-FLAG-CIC-S 
(60ng) and pcDNA3.1-FLAG-ATXN1 (60ng) [37] using 
Lipofectamine2000 (Invitrogen, NY, USA) according to 
the manufacturer’s instruction. The cells were lysed 48h 
later, and luciferase activities were analyzed using the 
Dual-Luciferase Reporter Assay System (Promega, WI, 
USA) according to the manufacturer’s protocol. 
Lentivirus production and transduction
Non-silencing control shRNA (Cat no. RHS4346) 
and shCIC expressing lentiviral vectors (pGIPZ) were 
purchased from Open Biosystems. The clone IDs for 
shCIC-1, shCIC-2, and shCIC-3 are V3LHS-358902, 
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V3LHS-408353, and V3LHS-358903, respectively. 
Lentivirus was produced by co-transfection of HEK-293T 
cells with pGIPZ-shCIC and plasmids for viral particles 
using FuGENE (Promega, WI, USA). Viral supernatants 
were collected at 48 h post-transfection and used to 
infect into the PC-3 and LNCaP cells pre-seeded with 
approximately 50% confluence. Puromycin was added 
to select drug-resistant pools at 48 h post-infection. For 
overexpression of CIC-S, CIC-L, and CRABP1, lentivirus 
was produced by the same protocol using the cloned 
pHAGE-FLAG-CIC-S, pHAGE-FLAG-CIC-L, pHAGE-
FLAG-CRABP1, or pHAGE-FLAG control plasmid. Viral 
supernatants were collected at 48 h post-transfection and 
used to infect into the PC-3 cells for 3 sequential days. The 
cells were used for further biochemical assays as specified 
in each experiment.
Western blot
Cells were lysed with RIPA buffer (50mM Tris (pH 
7.4), 150mM NaCl, 0.5% Sodium deoxycholate, 0.1% 
SDS, 1% Triton X-100) containing protease inhibitor 
cocktail tablets (Roche, CA, USA). Western blot analysis 
was performed as described previously[8] using primary 
antibodies as follows: rabbit anti-CIC (1:1000)[8], rabbit 
anti-CRABP1 (1:200) (Cell Signaling Technology, 
MA, USA), mouse anti-β-actin (1:2500) (Santa Cruz 
Biotechnology, TX, USA), and rabbit anti-FLAG 
(1:1000) (Sigma-Aldrich, MO, USA). The western blot 
images were obtained using ImageQuant LAS 4000 (GE 
Healthcare Life Science, PA, USA) and quantified with 
Image J software. 
RNA extraction and quantitative RT-PCR
Total RNA was extracted using Trizol reagent 
(Invitrogen, NY, USA) and subjected to cDNA 
synthesis using random hexamer and GoScript™ 
Reverse Transcription System (Promega, WI, USA) 
according to the manufacturer’s instructions. SYBR 
Green real-time PCR master mix (TOYOBO, NY, 
USA) was used for PCR reactions. Primers used 
for qRT-PCR are as follows: CRABP1 forward; 
5’-GCAGCAGCGAGAATTTCGAC-3’, and reverse; 
5’-CGTGGTGGATGTCTTGATGTAGA-3’. ETV1 
forward; 5’-ACACCTGTGTTGTCCCAGAA-3’, and 
reverse; 5’-GTTGGTATGTGGGTCCTTCC-3’. ETV4 
forward; 5’-GATGAAAGCCGGATACTTGGAC-3’, 
and reverse; 5’-TTCGCGCAAGCTCCCATTT-3’. ETV5 
forward; 5’-CATCCTACATGAGAGGGGGTTA-3’, and 
reverse; 5’-AAGTATAATCGGGGATCTTTTTCA-3’. 
GAPDH forward; 5’-AGCCACATCGCTCAGACAC-3’, 
and reverse; 5’-GCCCAATACGACCAAATCC-3’. 18S 
rRNA forward; 5’-ATCAACTTTCGATGGTAGTCG-3’, 
and reverse; 5’-ACTCATTCCAATTACAGGGC-3’.
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) was 
performed manually. Briefly, control and FLAG-CIC-S 
expressing PC-3 cells were fixed in 1% formaldehyde. 
The cross-linked DNA was then sheared into about 200-
1000 base pairs in length with sonication. Ten percent of 
the sheared DNA was set aside as an input control. The 
rabbit anti-FLAG antibody (Sigma-Aldrich, MO, USA) 
was incubated with sheared DNA at 4 °C overnight 
with rotation, then the protein G agarose (Millipore, 
Darmstadt, Germany) was added. After that, protein/
DNA complexes were eluted from the agarose. The cross-
linking DNA was reversed to free DNA, and purified DNA 
was analyzed by qPCR using the primers that amplify 
CRABP1 promoter region containing the CIC-binding 
site (R2). The primers that amplify CRABP1 promoter 
region without CIC-biding sites (R1) were used as a 
negative control. The primer sequences are as follows: R1 
forward; 5’-CAGAGCCAGACCCTGTC-3’, and reverse; 
5’-CAGATGAAGGTGTCCACTC-3’. R2 forward; 
5’-AAATAATCACAGTTTAGGAAAC-3’, and reverse; 
5’-CACCTCAGCCAAACTGTAC-3’.
RNA sequencing and data analysis
For isolation of mRNA from total RNA, Oligotex 
mRNA mini kit (QIAGEN, CA, USA) was used 
according to the manufacturer’s instructions. The cDNA 
was synthesized by random hexamer and Superscript III 
reverse transcriptase (Invitrogen, NY, USA). The library 
for the mRNA sequencing was constructed and sequenced 
on the Genome Analyzer IIx (Illumina, USA) using the 
protocol described earlier [38]. We mapped sequencing 
reads to the human reference genome (hg18 RefSeq) using 
Tophat (v 2.0.9). Reads Per Kilobase of exon per Million 
aligned tags (RPKM) values for each transcript were 
calculated by Cufflinks (v 2.2.1) as well as identification 
of the differential expressed genes. The GEO accession 
number of RNA sequencing data is GSE64025.
Statistical analysis
For statistical analysis, all experiments were 
performed more than three times independently. Data are 
presented as mean ± standard error. Student’s t-test was 
used to determine significance between groups. For all 
statistical tests, the 0.05 level of confidence was accepted 
for statistical significance.
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